Target Name: MIR744
NCBI ID: G100126313
Review Report on MIR744 Target / Biomarker Content of Review Report on MIR744 Target / Biomarker
Other Name(s): hsa-miR-744-3p | MicroRNA 744 | microRNA 744 | mir-744 | hsa-mir-744 | MIRN744 | hsa-miR-744-5p

MIR744: Exploring the Potential as a Drug Target or Biomarker

In recent years, microRNAs (miRNAs) have garnered significant interest in the field of biomedical research. These small non-coding RNA molecules play a crucial role in the regulation of gene expression and have been linked to various diseases, including cancer. Among the growing list of miRNAs, MIR744 has emerged as a promising candidate for therapeutic intervention and as a potential biomarker for disease diagnosis and prognosis. In this article, we delve into the fascinating world of MIR744 and explore its potential as a drug target or biomarker.

The Basics of MIR744

MIR744 is a microRNA belonging to the family of miR-515. It is transcribed from a gene located on human chromosome 19 and consists of a single-stranded RNA molecule typically 22 nucleotides in length. miRNAs like MIR744 primarily exert their function by binding to the messenger RNA (mRNA) molecules, resulting in their degradation or inhibition of translation. This, in turn, leads to the downregulation of the target genes that are involved in various cellular processes.

MIR744 in Disease

Extensive research has revealed the involvement of MIR744 in various disease pathways. Multiple studies have reported dysregulation of MIR744 expression in various types of cancers, including colorectal cancer, hepatocellular carcinoma, and breast cancer. In these malignancies, altered MIR744 expression is often associated with tumor growth, metastasis, and drug resistance. Additionally, MIR744 has been implicated in other diseases, such as cardiovascular diseases and neurological disorders.

MIR744 as a Drug Target

The dysregulated expression of MIR744 in several diseases highlights its potential as a therapeutic target. Modulating MIR744 expression levels through the use of anti-miRNA oligonucleotides or miRNA mimics holds promise for the development of innovative treatment strategies. Preclinical studies targeting MIR744 in cancer have shown promising results, with downregulation of MIR744 leading to inhibited tumor growth and increased sensitivity to chemotherapy in various animal models. Furthermore, combining MIR744-targeting approaches with conventional therapies may potentially enhance treatment outcomes.

The Roadblocks and Challenges

While the therapeutic potential of MIR744 as a drug target is promising, several challenges need to be addressed before its clinical use. One key hurdle is the delivery of MIR744 modulators to specific tissues or cells. Strategies are being explored to improve the efficiency and specificity of delivery systems, such as nanoparticle-mediated delivery and targeted modification of oligonucleotides. Another challenge is the potential off-target effects of modulating MIR744, as miRNAs can regulate multiple genes simultaneously. Careful consideration and optimization of treatment regimens are necessary to minimize unintended consequences.

MIR744 as a Biomarker

In addition to its potential as a therapeutic target, MIR744 shows promise as a diagnostic or prognostic biomarker in various diseases. The dysregulated expression of MIR744 in certain cancers has been correlated with clinical outcome and patient survival. The detection of MIR744 in bodily fluids, such as blood or urine, provides a non-invasive and easily accessible means of monitoring disease progression and treatment response. Further research is needed to establish robust and validated MIR744 biomarker signatures for specific diseases, paving the way for personalized medicine approaches.

The Future of MIR744

As researchers unveil the complex mechanisms of miRNA regulation, including MIR744, the field of therapeutic targeting and biomarker discovery continues to advance. Translating the vast knowledge obtained from preclinical studies into clinical benefits remains a major objective. Continued efforts in elucidating the specific pathways influenced by MIR744 and improving delivery systems will contribute to the development of effective MIR744-based therapeutics. Additionally, large-scale studies are needed to validate the potential of MIR744 as a biomarker and to establish standardized protocols for its clinical utility.


MIR744 represents a fascinating microRNA with significant potential as a drug target and biomarker in various diseases. Its dysregulated expression in cancer and other pathological conditions underscores its involvement in disease processes and treatment response. Harnessing the therapeutic potential of MIR744 requires overcoming challenges associated with delivery and off-target effects. Concurrently, the exploration of MIR744 as a diagnostic or prognostic biomarker has the potential to revolutionize disease management and facilitate personalized medicine approaches. As research into MIR744 continues, the future holds promise for its translation into clinical practice.

Protein Name: MicroRNA 744

The "MIR744 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR744 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

MIR7515 | MIR758 | MIR759 | MIR760 | MIR761 | MIR762 | MIR762HG | MIR764 | MIR765 | MIR766 | MIR767 | MIR769 | MIR770 | MIR7702 | MIR7703 | MIR7704 | MIR7705 | MIR7706 | MIR7843 | MIR7844 | MIR7845 | MIR7846 | MIR7847 | MIR7848 | MIR7849 | MIR7850 | MIR7851 | MIR7854 | MIR7855 | MIR7856 | MIR7974 | MIR7975 | MIR7976 | MIR7977 | MIR802 | MIR8054 | MIR8055 | MIR8059 | MIR8060 | MIR8061 | MIR8063 | MIR8064 | MIR8067 | MIR8069-1 | MIR8070 | MIR8071-1 | MIR8071-2 | MIR8072 | MIR8073 | MIR8075 | MIR8076 | MIR8078 | MIR8080 | MIR8082 | MIR8084 | MIR8085 | MIR8087 | MIR8088 | MIR8089 | MIR8485 | MIR873 | MIR874 | MIR875 | MIR876 | MIR877 | MIR885 | MIR887 | MIR888 | MIR889 | MIR890 | MIR891A | MIR891B | MIR892A | MIR892B | MIR892C | MIR9-1 | MIR9-1HG | MIR9-2 | MIR9-3 | MIR9-3HG | MIR920 | MIR921 | MIR922 | MIR924 | MIR924HG | MIR92A1 | MIR92A2 | MIR92B | MIR93 | MIR933 | MIR934 | MIR935 | MIR936 | MIR937 | MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3